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Abstract
Background: Reactivation of hepatitis B virus (HBV), characterized by increased levels of serum HBV DNA, abnormal
liver function and hepatic failure, is a frequent complication of immunosuppressive therapy and chemotherapy in
patients with HBV infection. However, reactivation of occult HBV infection with immunosuppressive therapy or
chemotherapy is rare.
Case presentation: A 77-year-old man was diagnosed with nephrotic syndrome and IgM nephropathy with unclear
pathogenesis. Liver function was normal, HBV-related serum markers were negative and HBV DNA titer was below
the upper limits of normal. Two months following the start of prednisone therapy for his nephrotic syndrome,
laboratory tests revealed a substantial increase in serum transaminase levels (ALT: 490 IU/L; AST: 149 IU/L) and an
elevation of HBV DNA level (3.42×106 copies/ml). We tested stored kidney tissue for HBsAg and HBcAg using
immunohistochemistry and found the sample to be HBcAg positive, allowing us to confirm the etiology of
nephropathy as an occult HBV infection. The cause of the hepatitis was thought to be HBV reactivation, so we
immediately administered lamivudine. One month after the initiation of daily lamivudine treatment, laboratory tests
revealed that serum levels of transaminases had improved (ALT: 35 IU/L; AST: 17 IU/L). Patient examination one year
later showed that HBeAg had decreased with a concomitant increase of HBeAb, the quantity of HBV DNA was
undetectable, and liver function and renal function had stabilized.
Conclusion: This is the first report describing HBV reactivation in an occult HBV infection patient treated with oral
prednisone for nephrotic syndrome. HBV-associated antigen should be regularly tested for in patients with unknown
etiological glomerulonephritis in areas with high HBV viral popular and even in those with no clinical evidence for
diagnosis of HBV.
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Background
Hepatitis B virus (HBV) infection has been shown to
induce extrahepatic lesions, commonly through the de-
position of immune complexes, in different organs. HBV-
associated glomerulonephritis (HBVAN) is one of the
more important extrahepatic diseases, and nephrotic
syndrome is its most common clinical manifestation
[1-8]. Pathological types of HBVAN include membranous
nephropathy, minimal change nephropathy, mesangial
proliferative glomerulonephritis, membranoproliferative
glomerulonephritis and IgA nephropathy. Of these, mem-
branous nephropathy is the most common, and reports of
IgM nephropathy are rare.
Occult HBV infection is defined as the undetectable of
HBV DNA and the absence of HBV surface antigen in
plasma or serum of HBV-infected patients [1,9]. This
infection may persist in individuals for years before any
symptoms of overt HBV infection emerge. Previous stud-
ies reported that co-infection [10], drug abuse [11] and
immunosuppression [12] can trigger an increase of HBV
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This is the first report describing HBV reactivation in
an occult HBV infection patient treated with oral prednis-
one for nephrotic syndrome. HBV reactivation allowed for
definitive characterization of the pathogenesis of nephrotic
syndrome in this particular case, which has been difficult
in past cases.
Case presentation
A 77-year-old man was diagnosed with nephrotic syndrome
with laboratory tests showing urine protein of ++++,
urinary occult blood test of ++++, 24-hour urine
total protein of 9.99 g/L, serum albumin of 25.2 g/L,
creatinine (Cr) of 234 μmol/L and blood urea nitrogen
(BUN) of 13.5 mmol/L. Detection of HBV-related serum
makers by chemiluminescent immunoassay showed that
HBsAg, anti-HBs, hepatitis B e antigen (HBeAg), anti-
HBe and anti-HBc were all negative. Furthermore,
the HBV DNA titer was undetectable (<103 copies/ml).
Anti-hepatitis C virus (HCV) was negative, anti-hepatitis
E virus (HEV) was negative, and both alanine amino-
transferase (ALT) and aspartate aminotransferase (AST)
were normal (below 40 IU/L). To further confirm the
pathogenesis of nephrotic syndrome, the patient re-
ceived a renal biopsy. As shown in (Figure 1A,B,D),
the results showed IgM nephropathy (focal segmental
glomerulosclerosis and crescent formation) and diffuse
damage to the renal tubules and stroma. The pathological
diagnosis was nephrotic syndrome with IgM nephropa-
thy; however, the exact cause of nephrosis was unclear.
At that time, the patient was being administered prednis-
one at a dose of 50 mg once daily.
Two months after starting treatment, laboratory tests
revealed a substantial increase in serum transaminase
levels (AST: 149 IU/L; ALT: 490 IU/L), urine protein
of ++, urinary occult blood test of +++, 24-hour urine
total protein of 3.1 g/L, serum albumin of 28.1 g/L, Cr of
211 μmol/L and BUN of 19.3 mmol/L. Strangely, HBV
markers were now positive for HBsAg, HBcAb and
HBeAg, and the quantity of HBV DNA had increased
to 3.42×106 copies/ml. Anti-HCV and anti-HEV were
still negative, and autoimmune hepatitis indices, including
anti-nuclear antibody (ANA), anti-mitochondrial antibody
(AMA) and liver kidney microsomal antibody (LKM), and
serum markers related to other hepatitis infections, such as
hepatitis A virus (HAV), cytomegalovirus, Epstein-Barr
virus and herpes virus, were all negative. Ultrasound of the
liver showed chronic hepatic injury.
Pathological diagnosis using immunohistochemistry to
detect the existence of S-Ag or C-Ag in renal tissue is
currently regarded as the “gold standard” for diagnosis
of HBVAN. We therefore tested stored kidney tissue for
HBsAg and HBcAg using immunohistochemistry and
found the sample to be HBcAg positive (Figure 1C).
In addition, molecular analysis showed that the HBV
Figure 1 Image of renal biospy. A: Focal segmental glomerulosclerosis with glomerular capillary wall collapse, balloon adhesion and fibrous
small new moon body form. Surrounding the open capillary lumen, the mesangial area has no obvious proliferation. (silver staining, 400x).
B: Segmental glomerular sclerosis, capillary bundle segmental collapse, balloon adhesion and cell sex small new moon body form. (PAS staining, 400x).
C: HBcAg immunohistochemistry staining: HBcAg along the glomerular capillary wall and mesangial area; stage positive. (400x). D: Immunofluorescence:
The glomerulus and mesangial area along the grain; sample fluorescence distribution: LgG-, LgA-, LgM++, C3-, F-, C1q-.
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genotype was C with no HBV mutation in the pre-core
or core promoter regions, thus we concluded that the
cause of the acute hepatitis was HBV reactivation, and
the pathogenesis of nephrotic syndrome was attributed
to HBVAN. We immediately administered lamivudine at a
dose of 100 mg once daily. One month after starting the
daily lamivudine treatment, laboratory tests revealed that
the serum levels of aminotransferase (ALT) and aspartate
aminotransferase (AST) had improved (ALT: 35 U/L, AST:
17 U/L), the quantity of HBV DNA was 1.1×105 copies/ml,
BUN was 11.3 mmol/L and Cr was 119 μmol/L. One year
after starting the treatment for HBV reactivation, follow-up
tests showed that HBsAg was positive, HBsAb was nega-
tive, HBeAg was negative, HBeAb was positive, HBcAb
was positive, BUN was 10.8 mmol/L, Cr was 121 μmol/L
and HBV DNA was undetectable by real-time PCR.
Discussion
Occult HBV infection is defined as infection with detect-
able HBV DNA and surface antigen (HBsAg) in the blood
[9]. This infection may persist in individuals for years be-
fore any symptoms of overt HBV infection emerge, and the
causes associated with the transition from an overt HBV
infection to an occult infection are currently unknown.
HBVAN is an extrahepatic manifestation of HBV in-
fection, and its main clinical manifestation is nephrotic
syndrome, which predominantly occurs during child-
hood and in males [1-6]; however, the number of reports
on adult patients is very limited [7,8]. Data suggests that,
compared to adults, the prognosis of HBVAN is more fa-
vorable in children and progression to renal failure is more
rare [6,8]. Pathological types of HBVAN include membran-
ous nephropathy, minimal change nephropathy, mesangial
proliferative glomerulonephritis, membranoproliferative
glomerulonephritis and IgA nephropathy. Of these, mem-
branous nephropathy is the most common, and reports of
IgM nephropathy are rare [1-8]. IgM nephropathy, a min-
imal change nephropathy rarely associated with HBVAN,
is defined by the presence of diffuse and global mesangial
deposits of IgM [13]. Many glomerulopathies are accom-
panied by IgM deposition, so some experts have sug-
gested the classification of IgM nephropathy as its own
subtype of minimal change nephropathy and an inde-
pendent diagnosis of IgM nephropathy past a certain
level of deposition intensity. The pathogenesis of IgM
nephropathy is currently unclear, but the accepted view
of some authorities is that immune complex deposition
may cause injury to the glomerular filtration membrane,
and the deposited antigen may originate from microbes,
drugs or heavy metals [13]. In our case, HBV antigen com-
plex deposition in the glomerular filtration membrane may
have led to the observed injury.
A ‘full house’ (IgG, IgA, IgM, C3 and C1q) positive
immunoflurescence staining is typically included in the
pathological diagnosis of HBVGN. The patient in this case
report was misdiagnosed due to the absence of ‘full house’
positive staining, instead having only IgM-positive staining,
and lack of positive clinical proof of HBV-associated
markers in the serum. Given the presence of IgM, it is pos-
sible that, during the early stages of HBV development, the
low HBV DNA load and low levels of other related anti-
gens allowed for the specific deposition of IgM in the
glomerular filtration membrane. Increasing diagnostic
experience suggests that positive antigen or visible viral
particles in the tissue are more important than previously
thought for diagnosis. These patients could potentially ex-
hibit a positive serum test upon subsequent follow-up.
Nephrotic syndrome was the original clinical manifest-
ation of our patient, and a renal biopsy was taken to
confirm pathology. Chronic HBV was not recognized, as
HBV-related serum markers were negative and HBV
DNA was below the upper limits of normal, so HBV-
related antigen detection with immunohistochemistry was
subsequently ignored. Further analysis of the biopsy results
revealed IgM nephropathy, of which previous reports are
few. The patient was administered the immunosuppressive
drug prednisone to treat the nephrotic syndrome with-
out preemptive therapy with antiviral drugs. Two months
later, elevation of ALT and AST and detectable HBV DNA
suggested a hepatitis B flare, which was likely due to
the prolonged duration of immunosuppressive therapy
resulting in HBV reactivation.
The HBV genotype influences clinical outcomes, serum
HBV DNA levels and mutational patterns in the pre-core
and core promoter regions [14]. For this particular patient,
the HBV genotype was C, but serum HBV DNA levels at
the time we initiated treatment with prednisone were low,
and no HBV mutations were observed in the pre-core or
core promoter regions. These findings lead us to surmise
that HBV genotype directly influences HBV reactivation
associated with immunotherapy. The inhibition of prednis-
one may be relevant to the replication of HBV, though the
specific mechanism remains unclear.
Preemptive therapy with lamivudine for HBsAg-positive
patients undergoing chemotherapy reduces the risk of
HBV reactivation and HBV-associated morbidity and
mortality [15]. Meanwhile, improvements in liver disease
and renal function have been reported following clear-
ance of HBsAg [16]. We therefore treated the patient
with lamivudine to repress the replication of HBV DNA,
expecting subsequent improvement of renal function.
One month after initiating lamivudine treatment, liver
function was improved and renal function had not wors-
ened. The patients remained on lamivudine (100 mg/day)
therapy for one year. Follow-up tests showed that HBsAg
was positive, HBsAb was negative, HBeAg was negative,
HBeAb was positive, HBcAb was positive, BUN was 10.8
mmol/L, Cr was 121 μmol/L, urine protein of +, urinary
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occult blood test of ++, 24-hour urine total protein of
2.14 g/L, serum albumin of 30.2 g/L, and HBV DNA was
undetectable by real-time PCR. The main indeces for
liver function include ALT, AST and total bilirubin
(TBIL) were all below the upper limits of normal. Total
cholesterol (TC) and thyroglobulin (Tg) levels were 7.4
mmol/L and 2.5 mmol/L, respectively.
Conclusion
In conclusion, HBV-associated antigen should be regu-
larly tested for in patients with unknown etiological
glomerulonephritis in areas with high HBV viral popular
and even in those with no clinical evidence for diagnosis
of HBV. IgM nephropathy as a pathological diagnosis
should not be ignored in cases of HBVAN, especially in
older patients. Following a definite diagnosis, if a patient
with HBV infection is to be treated with immunosup-
pressive agents, preemptive therapy with antiviral agents
is recommended for its contribution to decreasing HBV
reactivation and hepatitis B flare.
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